Sign up to The Irish Times Archive (1859 - 2008)My Account »
Tue 11 Nov 2008Risks outweigh the benefits
OBESE PATIENTS in the Republic have lost a potentially useful weapon in the fight against the condition. That's the response of consultant endocrinologist Dr Donal O'Shea to the news that the anti-obesity drug Acomplia - used by about 3,000 people in Ireland - was being temporarily taken off the European market by manufacturer Sanofi-aventis because of a risk of psychiatric side effects.
"I was disappointed when Acomplia was withdrawn because it was a new class of anti-obesity medication," says O'Shea, who directs the State's largest public weight management clinic at St Columcille's Hospital in Loughlinstown.
Choose a Subscription type - required
